Background:
- Cabozantinib is a drug that slows the growth of blood vessels that feed tumors. It is
approved for medullary thyroid cancer. However, studies have shown that prostate and ovarian
tumors respond to it. Researchers want see if cabozantinib can be a safe and effective
treatment for urothelial cancer.
Objectives:
- To test the safety and effectiveness of cabozantinib for advanced urothelial cancer.
Eligibility:
- Individuals at least 18 years of age who have advanced urothelial cancer that has not
responded to standard treatments.
Design:
- Participants will be screened with a physical exam and medical history. Blood and urine
samples will be collected. Tumor tissue samples will also be collected. Imaging studies
will also be performed.
- Participants will take cabozantinib by mouth once per day on each day of a 28-day cycle.
- Treatment will be monitored with frequent blood tests and imaging studies.
- Participants will continue to take the study drug for as long as their cancer does not
worsen and side effects are not too severe.